Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Germany(1,303/week)
    • France(1,092/week)
    • Poland(997/week)
    • Spain(579/week)
    • Czechia(342/week)
    • View all (7,044/week)
  • News
    • United States(473/week)
    • Manufacturing(356/week)
    • Energy(241/week)
    • Technology(372/week)
    • Other Manufacturing(311/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Sintilimab

Aug 12, 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Jun 21, 2020
Innovent Announces The Stock Exchange of Hong Kong Limited Approved the "B" Marker Removal from the Company's Stock Symbol in the HKEX
Jun 19, 2020
Innovent Announces the NMPA Granted Marketing Approval for BYVASDA® (Bevacizumab Biosimilar) in China
Jun 02, 2020
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
Jun 01, 2020
Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
May 31, 2020
Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
May 31, 2020
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
May 25, 2020
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
May 18, 2020
Innovent Biologics and MD Anderson Announce a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT® (Sintilimab Injection) in Rare Cancers
May 14, 2020
Innovent Announces Key Results from a Number of Clinical Studies to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
May 13, 2020
TYVYT® (Sintilimab Injection) ORIENT-2 Study Met its Primary Endpoint of Overall Survival in the Second-Line Treatment of Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Apr 27, 2020
Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China
Apr 23, 2020
Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum as First-Line Therapy in Non-squamous NSCLC
Mar 30, 2020
Innovent Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Progress
Mar 25, 2020
Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China
Jan 12, 2020
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
Jan 07, 2020
Sirnaomics and Innovent Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining STP705 and Sintilimab in the US
Jan 07, 2020
Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US
  •  
  • Page 1
  • ››

Latest News

Jul 4, 2022

Port Decarbonization: the First High-powered Hydrogen Barge for the Electrification of Ships at Berth

Jul 4, 2022

Technip Energies Awarded a Large EPC Contract by Hafslund Oslo Celsio for a World-First Carbon Capture and...

Jul 4, 2022

Japan protests Chinese navy sailing near disputed islands

Jul 3, 2022

UK probes hacking of army's Twitter, YouTube accounts

Jul 3, 2022

Sweden refuses to deny deportations to Turkey part of NATO deal

Jul 3, 2022

Virgin Orbit Successfully Launches ‘Straight Up’ Mission

Jul 2, 2022

With a Focus on Safety and Customers, PG&E Names New Leaders In Electric Operations, and Gas and Electric...

Jul 2, 2022

Spain, Mali FMs speak after row over NATO remarks

View all News

Agenda

17
November
The NetherlandsAhoy, Rotterdam
NIDV Exhibition Defence and Security, November 17, 2022, Ahoy Rotterdam
The NIDV Exhibition Defence and Security (NEDS) is the annual event for the Defence and Security industry and...
02
November
GreeceAthens
mastMED 2022 - Maritime/Air Systems & Technologies, 2-4 November, Athens, Greece
“The Mediterranean: Laboratory for Naval Warfare” Between 2–4 November 2022, Athens will be the first Greek city to...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
© 2022 EPICOS
Made by Wedia